Trulieve (TRLV) Q2 2026 earnings review
Strategic Restructuring Crushes GAAP Income but Unlocks NYSE Listing
Trulieve's Q2 was defined by a massive strategic pivot: the deconsolidation of its mixed-use 'Harvest' operations to isolate its medical-only business. This move allowed the company to become the first U.S. cannabis operator to list on the NYSE (ticker: TRLV) following the federal Schedule III rescheduling. However, it came at a steep optical cost—a $407 million charge that drove GAAP net loss to $406 million. Looking past the accounting noise, the remaining core medical business is highly profitable, boasting a 63% gross margin and generating $20.4 million in adjusted net income. While top-line revenue will shrink significantly in Q3 as the Harvest assets are removed from the P&L, the elimination of punitive 280E taxes sets the stage for drastically improved underlying cash generation.
🐂 Bull Case
The rescheduling of state-licensed medical marijuana to Schedule III removes the punitive 280E tax burden. The remaining medical-only operations will now be taxed on pre-tax income rather than gross profit, massively improving cash flow.
Stripping out the deconsolidated assets, Trulieve's pure-play medical operations delivered a superior 63% gross margin in Q2, compared to the consolidated 60%. Medical-only traffic also increased 6% sequentially.
🐻 Bear Case
By moving Harvest operations off the consolidated P&L, Trulieve is shedding significant revenue. Q3 guidance of ~$222 million represents a steep ~23% drop from Q1's $286.8 million peak.
While Trulieve retains a 90% economic interest in Harvest, it loses operating control and top-line recognition of key mixed-use growth markets like Maryland, Ohio, and Arizona.
⚖️ Verdict: ⚪
Neutral. The optical shock of the $406M net loss and the incoming Q3 revenue contraction are painful on the surface. However, the strategic trade-off—gaining an NYSE listing and escaping 280E taxation—positions the underlying medical business to generate far superior long-term cash flow.
Key Themes
The Harvest Deconsolidation and NYSE Uplisting
On June 3, Trulieve executed a complex corporate restructuring to separate its DEA-registered medical-only operations from its mixed-use (adult and medical) 'Harvest' markets. This 'ringfencing' was the key to unlocking the holy grail for U.S. multi-state operators: a major U.S. exchange listing. Trading on the NYSE drastically improves institutional access to the stock. While it triggered a one-time $403.3 million deconsolidation loss, adjusted net income remained stable at $20.4 million.
Macro Tailwind: Schedule III and the $598M Tax Reversal Potential
The DOJ's final order to reschedule medical marijuana to Schedule III is the most significant regulatory catalyst in the industry's history. It immediately removes the 280E tax penalty for Trulieve's remaining operations. Furthermore, Trulieve has aggressively challenged 280E applicability back to 2019, carrying a massive $598.2 million uncertain tax position liability on its balance sheet. If the government grants retroactive tax relief, this liability would reverse as a monumental one-time gain.
Growth Markets Sacrificed for Regulatory Compliance
To achieve the NYSE listing, Trulieve had to sever its mixed-use operations. This means deconsolidating 34 dispensaries and 0.5 million square feet of capacity in highly lucrative, transitioning markets like Ohio, Maryland, and Arizona. While management highlights the 90% retained economic interest, the loss of top-line revenue recognition and direct operational control in these high-growth states contradicts the broader industry narrative of expanding into adult-use markets.
Brand Dominance in the Core Florida Market
In Florida, the largest U.S. medical market, Trulieve maintains overwhelming dominance with 170 dispensaries (22% of retail doors). The company sold 56% more flower and 20% more oil per store than the state average in Q2. Specific in-house brands like Modern Flower and Roll One accounted for nearly half of all units sold across the network, underscoring strong product market fit and customer loyalty (78% retention in medical-only markets).
Debt Load and High Interest Costs Remain
Despite the restructuring and tax relief, Trulieve still carries a heavy capital structure. The balance sheet holds $289 million in debt at a blended interest rate of 9.6%. This resulted in $12.8 million in net interest expense in Q2 alone. While the company is generating positive free cash flow, servicing this high-cost debt will continue to drag on profitability until a refinancing event occurs.
Initiation of Share Repurchases
Signaling confidence in its post-restructuring cash flow profile, Trulieve announced a share repurchase program for up to $50 million (or 8.5 million subordinate voting shares). With cash and equivalents swelling to $325.4 million at quarter-end, the company has the liquidity to aggressively buy back stock while the market digests the complex GAAP accounting noise from the Q2 print.
Other KPIs
Stable. While down 11% YoY from $110.6M in 25Q2 due to a shrinking overall footprint, the Adjusted EBITDA margin expanded sequentially to 36.2% (from 35.0% in 26Q1). This indicates that the core operations are actually becoming more efficient despite the revenue drop.
Decelerating sequentially. Down from $42.2 million in 26Q1, primarily driven by a sequential increase in capital expenditures ($21.0M vs $13.5M in Q1) as the company invests in growth markets like Georgia and Texas. First-half FCF stands at a healthy $74.4 million.
Accelerating vs the consolidated footprint. By isolating the medical operations from the mixed-use Harvest assets, the pro forma gross margin profile improved by 300 basis points compared to the 60% reported consolidated gross margin. This proves the underlying profitability of the pure medical model.
Guidance
Reversing. Management expects Q3 reported revenue to be comparable to Q2's medical-only revenue. This represents an optical contraction of ~18% from Q2's reported $271 million, entirely driven by the deconsolidation of the Harvest assets rather than a deterioration in underlying demand.
Decelerating from prior guidance. The company lowered its operating cash flow target from $250 million to $225 million, explicitly citing the lost cash flow contribution from the deconsolidated Harvest transaction.
Accelerating. Management increased the CapEx budget from the prior $85 million expectation. The additional $10 million is earmarked specifically for investments in emerging medical markets, primarily ramping up production and retail footprints in Georgia and Texas.
Key Questions
Harvest Economic Interest Mechanics
You retain a 90% economic interest in the deconsolidated Harvest operations. How exactly will the financial upside from adult-use markets like Ohio and Maryland be recognized on Trulieve's future P&L, and what is the timing of those cash flows?
Resolution of 280E Tax Liability
With the $598 million uncertain tax position liability on the balance sheet, what are the specific legal or regulatory milestones required to trigger the reversal of this liability into a one-time gain?
Capital Allocation Priorities
You announced a $50 million share repurchase program while carrying $289 million in debt at 9.6%. How are you weighing the ROI of share buybacks versus retiring high-cost debt in the current interest rate environment?